Banoxantrone

Banoxantrone (AQ4N), as a prototype hypoxia selective cytotoxin, can be reduced to AQ4, a potent topoisomerase II inhibitor. Banoxantrone selectively kills hypoxic cells via an iNOS-dependent mechanism. Banoxantrone shows a potent cytotoxicity and hypoxia-selective effect enhanced by radiation[1][2].

Product Specifications

CAS Number

[136470-65-0]

Product Name Alternative

AQ4N

UNSPSC

12352005

Target

NO Synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/banoxantrone.html

Solubility

10 mM in DMSO

Smiles

O=C1C2=C(C(O)=CC=C2O)C(C3=C(NCC[N+](C)(C)[O-])C=CC(NCC[N+](C)(C)[O-])=C13)=O

Molecular Formula

C22H28N4O6

Molecular Weight

444.48

References & Citations

[1]Hejmadi MV, et al. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br J Cancer. 1996 Feb;73 (4) :499-505. |[2]Mehibel M, et al. Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase. Oncol Rep. 2016 Apr;35 (4) :1925-32.